GB201813677D0 - Calcitonin mimetics for treating diseases and disorders - Google Patents

Calcitonin mimetics for treating diseases and disorders

Info

Publication number
GB201813677D0
GB201813677D0 GBGB1813677.0A GB201813677A GB201813677D0 GB 201813677 D0 GB201813677 D0 GB 201813677D0 GB 201813677 A GB201813677 A GB 201813677A GB 201813677 D0 GB201813677 D0 GB 201813677D0
Authority
GB
United Kingdom
Prior art keywords
disorders
treating diseases
calcitonin mimetics
calcitonin
mimetics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1813677.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KeyBioscience AG
Original Assignee
KeyBioscience AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KeyBioscience AG filed Critical KeyBioscience AG
Priority to GBGB1813677.0A priority Critical patent/GB201813677D0/en
Publication of GB201813677D0 publication Critical patent/GB201813677D0/en
Priority to PCT/EP2019/072535 priority patent/WO2020039052A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1813677.0A 2018-08-22 2018-08-22 Calcitonin mimetics for treating diseases and disorders Ceased GB201813677D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1813677.0A GB201813677D0 (en) 2018-08-22 2018-08-22 Calcitonin mimetics for treating diseases and disorders
PCT/EP2019/072535 WO2020039052A1 (en) 2018-08-22 2019-08-22 Calcitonin mimetics for treating diseases and disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1813677.0A GB201813677D0 (en) 2018-08-22 2018-08-22 Calcitonin mimetics for treating diseases and disorders

Publications (1)

Publication Number Publication Date
GB201813677D0 true GB201813677D0 (en) 2018-10-03

Family

ID=63668229

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1813677.0A Ceased GB201813677D0 (en) 2018-08-22 2018-08-22 Calcitonin mimetics for treating diseases and disorders

Country Status (2)

Country Link
GB (1) GB201813677D0 (en)
WO (1) WO2020039052A1 (en)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
DK163689A (en) * 1988-04-08 1989-10-30 Sandoz Ag PEPTIDE DERIVATIVES
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5698672A (en) * 1995-04-04 1997-12-16 Zymogenetics, Inc. Synthetic calcitonin mimetics
US5698521A (en) * 1995-04-04 1997-12-16 Zymogenetics, Inc. Native calcitonin mimetics
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
HUP0001272A3 (en) 1997-04-16 2012-12-28 Unigene Lab Inc Direct expression of peptides into culture media
CN1329502A (en) 1998-12-04 2002-01-02 普罗瓦利斯英国有限公司 Pharmaceutical compositions containing insulin
IL145546A0 (en) 1999-04-05 2002-06-30 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
JP2006521366A (en) 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド Solid oral dosage forms containing seamless microcapsules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
EP1638517A4 (en) * 2003-06-30 2010-01-06 Univ Tel Aviv Future Tech Dev Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
PL1651249T3 (en) 2003-07-23 2013-04-30 Novartis Ag Use of calcitonin in osteoarthritis
EP1670500A2 (en) 2003-09-17 2006-06-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
JP2008506750A (en) 2004-07-22 2008-03-06 ティオマトリックス・フォルシュンクス・ウント・べラートゥンクス・ゲーエムベーハー Use of compounds containing thiol groups as exhaust pump inhibitors
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
EP1907561B1 (en) 2005-06-24 2013-08-28 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
JP5222727B2 (en) 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
PT1834635E (en) 2006-03-13 2011-10-13 Advanced In Vitro Cell Technologies S L Stable nanocapsule systems for the administration of active molecules
CA2648594C (en) 2006-04-07 2012-10-16 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
AU2012332265B2 (en) 2011-11-02 2016-11-10 Keybioscience Ag Peptide analogs for treating diseases and disorders
HUE037663T2 (en) 2013-11-14 2018-09-28 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201500263D0 (en) * 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders

Also Published As

Publication number Publication date
WO2020039052A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
IL269174A (en) Methods for treating complement-mediated diseases and disorders
IL280710A (en) Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
HRP20190356T1 (en) Calcitonin mimetics for treating diseases and disorders
HK1257583A1 (en) Medicine for preventing and treating fat metabolism disorders and related diseases and use of the medicine
IL275985A (en) Compositions and methods for treating retinal disorders
IL253026A0 (en) Calcitonin analogues for treating diseases and disorders
IL284029B1 (en) Peptides for treatment and prevention of diabetes and associated disorders
GB201704429D0 (en) Calcitonin mimetics for treating diseases and disorders
PT3810128T (en) Compositions for treating and/or preventing protein-aggregation diseases
GB201813677D0 (en) Calcitonin mimetics for treating diseases and disorders
GB201711838D0 (en) Calcitonin mimetics for treating diseases and disorders
GB201704355D0 (en) Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201414706D0 (en) Calcitonin mimetics for treating diseases and disorders
GB201808159D0 (en) Therapeutic compositions for treating neurocognative, neurodevelopmental and psychocognitive disorders
GB201807611D0 (en) Methods for assessing and treating complement-related disorders
SG11202007642RA (en) Treatment of disorders with tasimelteon
IL276697A (en) 3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of cannabinoids-related disorders
GB201902790D0 (en) Methods for assessing and treating complement-related disorders
HK1255631A1 (en) Pharmaceutical composition for preventing and treating sleep disorders
GB201320112D0 (en) Calcitonin Mimetics for treating diseases and disorders

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)